Massachusetts General Hospital is newest SOMAscan™ assay site
SomaLogic, Inc. announced today that Massachusetts General Hospital (MGH) will be the first Boston-area biomedical research center to perform on-site studies using the SOMAscan™ assay, a breakthrough proteomics platform that can measure more than a thousand proteins in a small amount of blood or other biological sample. The SOMAscan assay will be performed under the direction of Robert Gerszten, MD, Director of Clinical and Translational Research of the MGH Heart Center and Professor of Medicine at Harvard Medical School. It is expected that the SOMAscan assay will be installed and fully functional at MGH by mid-fall of 2014.
“We are delighted to partner with such a world-class institute as Massachusetts General Hospital to bring our powerful technology to more researchers,” said Byron Hewett, Chief Executive Officer of SomaLogic. “The leadership of Dr. Gerszten, together with MGH’s deep expertise in applying cutting edge biotechnology tools to critical biomedical questions, will help ensure that the SOMAscan assay will contribute to new biomarker discoveries, and potentially to new therapeutic approaches for treating diseases.”
Compared to other current proteomic technologies, the SOMAscan proteomic assay’s breadth and depth of coverage of the proteome offers significant new potential for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development.
“We have used the SOMAscan assay in previous work in mice and humans, and I believe that a technology like this has the potential to accelerate translational research across many different diseases and conditions. We expect to be able to offer this assay to our colleagues, as they realize the potential of this platform for their own translational research efforts,” said Dr. Gerszten.
SomaLogic is continuing to expand access to its SOMAscan platform through its placement in leading academic research centers, and anticipates announcing several additional SOMAscan assay sites by the end of 2014.